Lung cancer: A silent threat with high lethality globally
Lung cancer is a highly aggressive and highly fatal disease, responsible for 1.8 million deaths annually in the world, which represents 18.7% of all cancer deaths. Each year, approximately 2.4 million new cases of this disease are diagnosed, which is classified into two main types: non-small cell lung cancer (NSCLC), which accounts for 85% of cases, and small cell lung cancer (SCLC), which tends to be less common but faster in growing and spreading.
One of the characteristics of NSCLC is its relationship with certain genetic biomarkers that contribute to tumor growth, facilitating the development of specific therapies and treatments such as immunotherapy. Biomarkers, such as mutations in EGFR, ALK, KRAS, and other genes, are key to personalizing treatment and improving patient prognosis. However, the majority of lung cancer cases are diagnosed in advanced stages, limiting options to palliative treatments and significantly affecting survival rates.
In terms of diagnosis, lung cancer can be detected through a combination of imaging studies, laboratory tests, and biopsies. Smoking, family history, exposure to wood smoke, and chest radiotherapy are highlighted as relevant risk factors.
AstraZeneca, within the framework of World Lung Cancer Day, reaffirms its commitment to the fight against this disease. With its “Identify it: no one is exempt from lung cancer” campaign, the company seeks to raise awareness about the importance of early diagnosis, identification of risk factors and good health practices. This campaign focuses on raising awareness among the population and promoting collaboration between health institutions, researchers and society to mitigate the impact of lung cancer at a regional and global level.
